Member Info for stocksaint

This is about a pilot. Not in routine use anywhere yet.

Not really. Because for proper market access in USA you need insurers approval, and Medicare approval as well, even after FDA.

James, that post was about aihl, a different product.

The initial production will just be to cover demonstration, training and in the event that an actual order is received soon.

They'll all be trying to secure central lab testing first for this before considering POC as alternative option, as that's what NICE just told them to do.

There was already a massive dump at 5p this morning Bearded. Did you get trapped?

People have been waiting for a sales RNS from GDR for 10 years or more. Even a sales forecast would be a milestone.

Just pump and dump crew again. It bound to drop fast once they move out. Mugs left in will be looking for a sales RNS that never comes.

LOL James. You might want to reread that bit. GDR's test is NOT a lab test.....

Lol sharedealer, if GDR had the entire UK market for this, revenue would be about £8.5m. Will they get 5% or 10% per annum of this market for a couple of years and then nothing as lab testing gets completely sorted?

So what's peeps predictions for UK sales for GDR stroke product seeing as lab testing is preferred option? 0, £1m per year, £200,000 per year?

Will GDR get ANY UK sales from this??:

"A preference for laboratory testing is

expressed in the recommendations and is also discussed in the rationale

and in sections 3.8 and 3.13 in the draft guidance."

It's just NICE take into account all sorts of things. But personally think they biased against POC already, that's the starting point. The genomic hubs strategy that they already put in place some time ago was about central lab testing. So they basically comparing other altenatives to what is already their prime strategy.

For anyone too lazy to use Google etc, this was the draft guidance (though not long to wait for real thing now):

Laboratory-based testing

1.2 Use laboratory-based testing for CYP2C19 genotype testing.

Point-of-care testing

1.3 Use the Genedrive CYP2C19 ID Kit point-of-care test for CYP2C19

genotype testing when laboratory-based testing is not available.

1.4 Use the Genomadix Cube point-of-care test when laboratory-based

testing and the Genedrive CYP2C19 ID Kit point-of-care test are not

available.

https://www.nice.org.uk/guidance/gid-dg10054/documents/514-2

To me it just because it not certain how much/little GDR can benefit from NICE recommendation for stroke product seeing as they appear to be recommending central lab testing as preferred strategy. Perhaps tomorrow they'll be more clarity to understand the benefit or not for GDR.

I expect this will go down more this week and hit 2.8p by close on either Wednesday or Thursday.

Some setup process/training would be required as well with PoC.

I.e 15 months after full green light from NICE received

But also I think it would take a "significant" amount of time to get GDR's POC rolled out across all NHS hospitals in the UK. I think they once said it would take about 15 months to get AIHL fully rolled out across all 210 baby units in the UK. So how long would it take to get the stroke test rolled out across all 1140 hospitals in the UK?

So Eureka, how much lab capacity is there in the genomic hubs at the moment? And how long would it take to increase it?

Though they're saying use central lab testing as first choice (only use PoC, if lab testing unavailabe).